Nurse Practitioner Program year 2025 Reported 2021–2025 Source: CMS Open Payments, 2026 publication

Frances Hopkins

Nurse Practitioner Sacramento, CA Nurse Practitioner

NPI 1497427835 CMS profile 11270162

1111 Exposition Blvd Ste 700, Sacramento, CA 95815

Open in the dashboard

General payments

$6,314

338 records reported · program years 2021–2025

Research payments

$0

Paid to them · None reported · program years 2021–2025

Ownership & investment interest

$0

None reported

Through program year 2025, Frances Hopkins of Sacramento, CA is reported in the CMS Open Payments database as having received $6,314 across 338 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 94th percentile of Nurse Practitioner profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

5 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $279 13
2024 General $2,587 144
2023 General $1,491 69
2022 General $1,679 101
2021 General $278 11

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Frances Hopkins
  • Nurse Practitioner median
  • Middle half of Nurse Practitioner
  • National median

In program year 2025, general payments to Frances Hopkins were reported at $279. Among 41,044 Nurse Practitioner profiles paid that year, the median was $174 and the middle half received between $55 and $557.

Show as a table
Year Frances Hopkins Nurse Practitioner median Middle half National median
2019 $0 $50 $22–$97 $163
2020 $0 $40 $16–$108 $114
2021 $278 $135 $40–$426 $132
2022 $1,679 $152 $48–$470 $149
2023 $1,491 $166 $54–$529 $160
2024 $2,587 $173 $55–$556 $164
2025 $279 $174 $55–$557 $169

Breakdown

Who paid General payments · program years 2021–2025
  1. UCB, Inc. $1,445 88 payments
  2. Neurelis, Inc. $1,144 47 payments
  3. SK Life Science, Inc. $830 36 payments
  4. Jazz Pharmaceuticals Inc. $548 39 payments
  5. Corium, Inc. $339 22 payments
  6. Teva Pharmaceuticals USA, Inc. $260 18 payments
  7. Biohaven Pharmaceutical Holding Company Ltd. $252 15 payments
  8. LivaNova USA, Inc. $216 12 payments
  9. Catalyst Pharmaceuticals, Inc. $201 7 payments
  10. Ironshore Pharmaceuticals Inc. $158 8 payments
  11. Other $921 46 payments

Every payment, record by record

What the payments were for General payments · program years 2021–2025
  1. Food and Beverage $6,314 338 payments
Products named General payments · program years 2021–2025
  1. VALTOCO $1,144 47 payments
  2. Briviact $792 36 payments
  3. Fintepla $583 51 payments
  4. Epidiolex $561 40 payments
  5. Azstarys $339 22 payments
  6. NURTEC ODT $287 17 payments
  7. AJOVY $218 15 payments
  8. VNS THERAPY SENTIVA MODEL 1000 GENERATOR $216 12 payments
  9. FYCOMPA $201 7 payments
  10. DAYBUE $134 7 payments
  11. Other $1,141 54 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Records

338 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Nurse Practitioner in California

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record